Which of the following information regarding Pneumovax 23 is TRUE?
 
a. Pneumococcal vaccine is administered intradermally as one 0.5-mL dose.
b. Pneumococcal vaccine MUST NOT be administered at the same time as influenza vaccine.
c. For any person who has received a dose of pneumococcal vaccine at age greater than 65 years, revaccination is not indicated.
d. PNEUMOVAX 23 is approved for use in children older than 1 year of age.

Which of the following information regarding Pneumovax 23 is TRUE?
 
a. Pneumococcal vaccine is administered intradermally as one 0.5-mL dose.
b. Pneumococcal vaccine MUST NOT be administered at the same time as influenza vaccine.
c. For any person who has received a dose of pneumococcal vaccine at age greater than 65 years, revaccination is not indicated.
d. PNEUMOVAX 23 is approved for use in children older than 1 year of age.
 
Answer:(c). PNEUMOVAX 23 is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine.
 
PNEUMOVAX 23 is NOT approved for use in children younger than 2 years of age because children in this age group do not develop an effective immune response to capsular types contained in the polysaccharide vaccine.
 
The Advisory Committee on Immunization Practices (ACIP) has recommendations for revaccination against pneumococcal disease for persons at high risk who were previously vaccinated with PNEUMOVAX 23. Routine revaccination of immunocompetent persons previously vaccinated with a 23-valent vaccine, is not recommended.
 
All persons in this category should receive the pneumococcal vaccine, including previously unvaccinated persons and persons who have not received vaccine within 5 years (and were <65 years of age at the time of vaccination). For any person who has received a dose of pneumococcal vaccine at age greater than 65 years, revaccination is not indicated.
 
Pneumococcal vaccine is administered intramuscularly or subcutaneously as one 0.5-mL dose. Pneumococcal vaccine may be administered at the same time as influenza vaccine (by separate injection in the other arm) without an increase in side effects or decreased antibody response to either vaccine.

Pneumococcal vaccine also may be administered concurrently with other vaccines. The administration of pneumococcal vaccine with combined diphtheria, tetanus, and pertussis (DTP); poliovirus; or other vaccines does not increase the severity of reactions or diminish antibody responses.
 
Canadian and U.S. product labeling do say to consider separating administration of Zostavax and Pneumovax 23 by at least four weeks, since concurrent administration of these vaccines can reduce patients' immune responses to Zostavax.

www.pharmacyexam.com Try Our Naplex QBank.

What would be the new Acetaminophen strength in a reformulated Vicodin?
 
a. 500 mg
b. 300 mg
c. 325 mg
d. None of the above

What would be the new Acetaminophen strength in a reformulated Vicodin?
 
a. 500 mg
b. 300 mg
c. 325 mg
d. None of the above
 
Answer(b): 300 mg. On January 13, 2011, the U.S. Food and Drug Administration (FDA) asked drug manufacturers to limit the strength of acetaminophen in prescription drug products, including combination acetaminophen and opioid products, to no more than 325 mg per dosage unit.
 
The FDA has stated that limiting the amount of acetaminophen per dosage unit in prescription products may reduce the risk of severe liver injury from acetaminophen overdosing.
 
The FDA requested this change be effected by January 2014. Abbott, the manufacturer of Vicodin, has complied with this directive ahead of the FDA's requested date and has introduced new formulations of Vicodin (Hydrocodone bitartrate and Acetaminophen tablets, USP) with reduced acetaminophen content in the third quarter of 2012.
 
Vicodin is available in the following new formulations:

1. VICODIN® (hydrocodone bitartrate and acetaminophen tablets, USP) 5 mg/300 mg
2. VICODIN ES® (hydrocodone bitartrate and acetaminophen tablets, USP) 7.5 mg/300 mg
3. VICODIN HP® (hydrocodone bitartrate and acetaminophen tablets, USP) 10 mg/300 mg
 
www.pharmacyexam.com Try our Naplex Questions QBank.

Brintellix is indicated for the treatment of:
 
a. Hypertension
b. Major Depressive Disorder
c. Arthritis
d. Diabetes mellitus
e. Male pattern baldness

Brintellix is indicated for the treatment of:
 
a. Hypertension
b. Major Depressive Disorder
c. Arthritis
d. Diabetes mellitus
e. Male pattern baldness

Answer(b): Major depressive disorder. The active ingredient found in Vortioxetine (Brintellix) is Vortioxetine. Each Vortioxetine (Brintellix) tablet contains 5 mg, 10 mg, 15 mg, or 20 mg of Vortioxetine, respectively. Vortioxetine (Brintellix) is indicated for the treatment of major depressive disorder (MDD).
 
The recommended starting dose is 10 mg administered orally once daily without regard to meals. Dosage should then be increased to 20 mg/day, as tolerated, because higher doses demonstrated better treatment effects in trials conducted in the United States. The efficacy and safety of doses above 20 mg/day have not been evaluated in controlled clinical trials. A dose decrease down to 5 mg/day may be considered for patients who do not tolerate higher doses.
 
At least 14 days should elapse between discontinuation of a MAOI intended to treat psychiatric disorders and initiation of therapy with Vortioxetine (Brintellix) to avoid the risk of Serotonin Syndrome. Conversely, at least 21 days should be allowed after stopping Vortioxetine (Brintellix) before starting an MAOI intended to treat psychiatric disorders.
 
Nausea, constipation, vomiting, serotonin toxicity and serotonin syndrome are commonly reported side effects of Vortioxetine (Brintellix).
 
www.pharmacyexam.com Try our Naplex Questions QBank.

Which of the following drugs shall be strictly avoided in a patient taking Paxil?
 
a. Lyrica
b. MS Contin
c. Brisdelle
d. Astagraf
e. Depakote

Which of the following drugs shall be strictly avoided in a patient taking Paxil?
 
a. Lyrica
b. MS Contin
c. Brisdelle
d. Astagraf
e. Depakote

Answer:(c) Paroxetine (Brisdelle) is an orally administered selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. Each pink capsule contains 7.5 mg Paroxetine base.
 
The recommended dosage of Paroxetine (Brisdelle) for the treatment of moderate to severe VMS is 7.5 mg once daily, at bedtime, with or without food.
 
Paroxetine (Brisdelle) is not indicated for the treatment of any psychiatric condition. Paroxetine (Brisdelle) contains a lower dose of paroxetine than that used to treat depression, obsessive compulsive disorder, panic disorder, generalized anxiety disorder, social anxiety disorder, and post-traumatic stress disorder.
 
Serotonin syndrome, abnormal bleeding, hyponatremia, mania/hypomania, seizure and suicidal thoughts and behavior are reported side effects of Paroxetine (Brisdelle).

www.pharmacyexam.com Try our Naplex Questions QBank.

Which of the following is the principal side effect of Zaltrap?
 
a. Tachycardia
b. Seizure
c. G.I perforation and bleeding
d. Ocular hypertension
e. Diarrhea

Which of the following is the principal side effect of Zaltrap?
 
a. Tachycardia
b. Seizure
c. G.I perforation and bleeding
d. Ocular hypertension
e. Diarrhea
 
Answer:(c). Ziv-aflibercept (Zaltrap) is a recombinant fusion protein consisting of Vascular Endothelial Growth Factor (VEGF)-binding portions from the extracellular domains of human VEGF Receptors 1 and 2 fused to the Fc portion of the human IgG1.
 
Ziv-aflibercept (Zaltrap), in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is indicated for patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen.
 
Administer Ziv-aflibercept (Zaltrap) 4 mg per kg as an intravenous (IV) infusion over 1 hour every two weeks. Administer Ziv-aflibercept (Zaltrap) prior to any component of the FOLFIRI regimen on the day of treatment.
 
Severe and sometimes fatal hemorrhage, including gastrointestinal (GI) hemorrhage, has been reported in the patients who have received Ziv-aflibercept (Zaltrap) in combination with FOLFIRI. Monitor patients for signs and symptoms of GI bleeding and other severe bleeding. Do not administer Ziv-aflibercept (Zaltrap) to patients with severe hemorrhage.
 
Gastrointestinal Perforation: Gastrointestinal (GI) perforation including fatal GI perforation can occur in patients receiving Ziv-aflibercept (Zaltrap). Discontinue Ziv-aflibercept (Zaltrap) therapy in patients who experience GI perforation.
 
Severe compromised wound healing can occur in patients receiving ZALTRAP/FOLFIRI. Discontinue Ziv-aflibercept (Zaltrap) in patients with compromised wound healing. Suspend Ziv-aflibercept (Zaltrap) for at least 4 weeks prior to elective surgery, and do not resume Ziv-aflibercept (Zaltrap) for at least 4 weeks following major surgery and until the surgical wound is fully healed.
 
www.pharmacyexam.com Try our Naplex Questions QBank.

Levomilnacipran is indicated for the treatment of:
 
a. Hypertension
b. Depression
c. Epilepsy
d. Renal carcinoma
e. Arrhythmia

Levomilnacipran is indicated for the treatment of:
 
a. Hypertension
b. Depression
c. Epilepsy
d. Renal carcinoma
e. Arrhythmia

Answer:(b). Levomilnacipran (Fetzima), a selective serotonin and norepinephrine reuptake inhibitor (SNRI), is indicated for the treatment of major depressive disorder (MDD).
 
The recommended dose range for Levomilnacipran (Fetzima) is 40 mg to 120 mg once daily, with or without food. Levomilnacipran (Fetzima) should be initiated at 20 mg once daily for 2 days and then increased to 40 mg once daily. Based on efficacy and tolerability, Levomilnacipran (Fetzima) may then be increased in increments of 40 mg at intervals of 2 or more days. The maximum recommended dose is 120 mg once daily.
 
At least 14 days should elapse between discontinuation of an MAOI intended to treat psychiatric disorders and initiation of therapy with Levomilnacipran (Fetzima). Conversely, at least 7 days should be allowed after stopping Levomilnacipran (Fetzima) before starting an MAOI antidepressant.
 
Suicidal thoughts and behaviors in adolescents and young adults, serotonin syndromes, elevated blood pressure, activation of mania/hypomania, seizure and hyponatremia are reported side effects of Levomilnacipran.

www.pharmacyexam.com Try our Naplex Questions QBank.
 

A pharmacist receives a new prescription for Meloxicam (Mobic). The prescription reads:

Take 7.5 mg by mouth every 8 hours with or without meals for the pain associated with rheumatoid arthritis x 30 days. Refill: 5 times.

Which of the following is True?
 
a. Fill it.
b. Call physician to clarify dosage strength.
c. Call physician to clarify indication of drug.
d. Call physician to clarify the frequency of dosing.
e. Change direction to take with meals after verifying with physician.

A pharmacist receives a new prescription for Meloxicam (Mobic). The prescription reads:

Take 7.5 mg by mouth every 8 hours with or without meals for the pain associated with rheumatoid arthritis x 30 days. Refill: 5 times.

Which of the following is True?
 
a. Fill it.
b. Call physician to clarify dosage strength.
c. Call physician to clarify indication of drug.
d. Call physician to clarify the frequency of dosing.
e. Change direction to take with meals after verifying with physician.

Answer: (d). Meloxicam (Mobic), an oxicam derivative, is a member of the enolic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). Each pastel yellow tablet contains 7.5 mg or 15 mg Meloxicam (Mobic) for oral administration.
 
Meloxicam (Mobic) is indicated for relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis and pauciarticular or polyarticular course Juvenile rheumatoid arthritis in patients 2 years of age and older.
 
For the relief of the signs and symptoms of arthritis the recommended starting and maintenance oral dose of Meloxicam (Mobic) is 7.5 mg once daily since the mean elimination half-life (t½) ranges from 15 hours to 20 hours. Some patients may receive additional benefit by increasing the dose to 15 mg once daily. It may be taken without regard to timing of meals.
 
Nonsteroidal anti-inflammatory drugs (NSAIDs) may cause an increased risk of serious cardiovascular (CV) thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.
 
NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse reactions including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events.

A pharmacist receives a new prescription for Propecia. The prescription reads:
 
Take 5 mg by mouth once daily with or without meals for male pattern baldness x 30 days.
 
Refill: 5 times
 
Which of the following is True?
 
a. Fill it.
b. Call physician to clarify dosage strength.
c. Call physician to clarify indication of drug.
d. Call physician to clarify a number of refills of drug.
e. Change direction to take with meals after verifying with physician.

A pharmacist receives a new prescription for Propecia. The prescription reads:
 
Take 5 mg by mouth once daily with or without meals for male pattern baldness x 30 days.
 
Refill: 5 times
 
Which of the following is True?
 
a. Fill it.
b. Call physician to clarify dosage strength.
c. Call physician to clarify indication of drug.
d. Call physician to clarify a number of refills of drug.
e. Change direction to take with meals after verifying with physician.

Answer: b
 
The active ingredient found in Propecia and Proscar is Finasteride.
 
Finasteride is a competitive and specific inhibitor of Type II 5-alpha-reductase. The development and enlargement of the prostate gland is dependent on the potent androgen, 5-alpha-dihydrotestosterone (DHT). By reducing the levels of dihydrotestosterone, Finasteride prevents the development and enlargement of the prostate gland.
 
Finasteride (Proscar) is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to:
 
1. Improve symptoms
2. Reduce the risk of acute urinary retention
3. Reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy.
 
The recommended dose of Proscar is 5 mg once daily taken with or without meals.
 
Finasteride (Propecia) is indicated for the treatment of male pattern hair loss (androgenetic alopecia) in MEN ONLY. The recommended dose of Propecia is 1 mg once daily taken with or without meals.
 
Therefore, the pharmacist should clarify the dosage strength with a prescribing physician since the prescription is written for Propecia but prescribed on bases of Proscar dose.
 
www.pharmacyexam.com Try our Naplex Questions QBank.

Which of the following is/are 5-alpha-reductase inhibitors?

I. Propecia
II. Avodart
III. Jalyn

a. I only
b. III only
c. I and II only
d. II and III only
e. All

Which of the following is/are 5-alpha-reductase inhibitors?

I. Propecia
II. Avodart
III. Jalyn

a. I only
b. III only
c. I and II only
d. II and III only
e. All

Answer: (e) All. 5-Alpha-reductase inhibitors block the action of 5-alpha-reductase, the enzyme that converts testosterone into dihydrotestosterone, which has greater affinity for androgen receptors. The activity of 5-alpha-reductase inhibitors results in increased levels of testosterone and decreased levels of dihydrotestosterone.

The development and enlargement of the prostate gland is dependent on the potent androgen, 5-alpha-dihydrotestosterone (DHT). By reducing the levels of dihydrotestosterone, 5-Alpha-Reductase inhibitors prevent the development and enlargement of the prostate gland.

5-Alpha-reductase inhibitors are used to treat baldness, prostate hyperplasia and prostate cancer.
Below is the list of 5-Alpha-Reductase inhibitors:

1. Finasteride = Proscar, Propecia
2. Dutasteride = Avodart
3. Dutasteride + Tamsulosin = Jalyn


Try our Naplex QBank. www.pharmacyexam.com

1. Georgia
2. Maryland
3. New Mexico
4. Utah
5. Illinois
6. Rhode Island
7. West Virginia